Comparative Pharmacology
Head-to-head clinical analysis: CEPHALEXIN versus DOCEFREZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEPHALEXIN versus DOCEFREZ.
CEPHALEXIN vs DOCEFREZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cephalexin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and disrupting cell wall cross-linking, leading to cell lysis and death.
Docetaxel binds to beta-tubulin, promoting microtubule assembly and inhibiting depolymerization, resulting in cell cycle arrest at G2/M phase and apoptosis.
Oral: 250-1000 mg every 6 hours; maximum 4 g/day.
75 mg/m² intravenously over 1 hour every 3 weeks.
None Documented
None Documented
0.5-1.2 hours in normal renal function; prolonged to 5-30 hours in severe renal impairment (CrCl <10 mL/min)
Clinical Note
moderateCephalexin + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Cephalexin."
Clinical Note
moderateCephalexin + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Cephalexin."
Clinical Note
moderateCephalexin + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Cephalexin."
Clinical Note
moderateCephalexin + Sulfisoxazole
Terminal elimination half-life is 4.5-6.0 hours in patients with normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl <30 mL/min).
Renal: 80-90% unchanged by glomerular filtration and tubular secretion; biliary: <5%; fecal: <1%
Primarily renal excretion (70-80% as unchanged drug) with hepatic metabolism contributing to biliary/fecal elimination (20-30%).
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic
"The metabolism of Sulfisoxazole can be decreased when combined with Cephalexin."